Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsApollomics Inc. · Solid TumorsRecruitingAPLMLead
- Enrollment
- Locked
- Primary completion
- Mar 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05065216Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)DiaMedica Therapeutics Inc · Acute StrokeRecruitingDMACLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05608681A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Eupraxia Pharmaceuticals Inc. · Eosinophilic EsophagitisRecruitingEPRXLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05922878Study of ALTO-300 in MDDAlto Neuroscience · Major Depressive DisorderRecruitingANROLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06182969A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.Ascentage Pharma Group Inc. · SLERecruitingAAPGLead
- Enrollment
- Locked
- Primary completion
- Apr 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited · Narcolepsy Type 1RecruitingCNTALead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06825702Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaKiora Pharmaceuticals, Inc. · Macular EdemaRecruitingKPRXLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06982508Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersNewAmsterdam Pharma · Antioxidant AbsorptionRecruitingNAMSLead
- Enrollment
- Locked
- Primary completion
- Sep 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07482657A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With...Enanta Pharmaceuticals, Inc · RSV InfectionRecruitingENTALead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07511816A Study of LY4515100 in Participants With Pain Following Third Molar RemovalEli Lilly and Company · Acute PainRecruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06387342Namodenoson Treatment of Advanced Pancreatic CancerCan-Fite BioPharma · Pancreatic AdenocarcinomaRecruitingCANFLead
- Enrollment
- Locked
- Primary completion
- Jul 15, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04641247A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyGlaxoSmithKline · Ovarian NeoplasmsRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Dec 28, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05789056Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT06953466Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT07017725A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune...CASI pharmaceuticals, Inc. · Chronic Immune ThrombocytopeniaRecruitingCASIFLead
- Enrollment
- Locked
- Primary completion
- Jun 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05913752A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) SubjectsClearmind Medicine Inc. · Alcohol Use DisorderRecruitingCMNDLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsAscentage Pharma Group Inc. · LiposarcomaRecruitingAAPGLead
- Enrollment
- Locked
- Primary completion
- Apr 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05027906Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantEledon Pharmaceuticals · Prevention of Rejection in Kidney TransplantRecruitingELDNLead
- Enrollment
- Locked
- Primary completion
- Jan 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06447025An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaRecruitingLRMRLead
- Enrollment
- Locked
- Primary completion
- Jan 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT07276373Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesCorcept Therapeutics · NeoplasmsRecruitingCORTLead
- Enrollment
- Locked
- Primary completion
- Sep 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05254171Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPanbela Therapeutics, Inc. · Pancreatic Cancer MetastaticRecruitingPBLALead
- Enrollment
- Locked
- Primary completion
- Aug 29, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT07355075A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate...Turn Therapeutics · Eczema Atopic DermatitisRecruitingTTRXLead
- Enrollment
- Locked
- Primary completion
- Jan 20, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.